Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model

Uterine leiomyosarcoma (LMS) contributes to a significant proportion of uterine cancer deaths. It is a rare and high-risk gynecological cancer. LMS is challenging to the treatment due to the resistance of several therapies. The activation of the Hedgehog (HH) pathway has been reported in several typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, Natalia, Ulin, Mara, Ali, Mohamed, Al-Hendy, Ayman, Carvalho, Katia Candido, Yang, Qiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Gynecologic Oncology: Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863774/
https://www.ncbi.nlm.nih.gov/pubmed/34642915
http://dx.doi.org/10.1007/s43032-021-00731-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863774/
https://www.ncbi.nlm.nih.gov/pubmed/34642915
http://dx.doi.org/10.1007/s43032-021-00731-y

Ejemplares similares